Please login to the form below

Not currently logged in
Email:
Password:

Acacia Pharma

This page shows the latest Acacia Pharma news and features for those working in and with pharma, biotech and healthcare.

Acacia finally gets FDA okay for first product Barhemsys

Acacia finally gets FDA okay for first product Barhemsys

Edison analyst predicts drug could reach $387m at peak. The long tale of Acacia Pharma’s efforts to bring its post-operative nausea and vomiting (PONV) drug Barhemsys to market is ... sedation. It licensed the drug from Cosmo Pharma in a deal that also

Latest news

  • Acacia eyes February FDA verdict for refiled nausea drug Barhemsys Acacia eyes February FDA verdict for refiled nausea drug Barhemsys

    Back on track after being turned down twice. Acacia Pharma’s experimental drug for post-operative nausea and vomiting (PONV) looks back on track, after being turned down twice by the ... Acacia’s Euronext-listed shares rose almost 3% on news of the

  • UK biotech booms in 2018, despite Brexit worries UK biotech booms in 2018, despite Brexit worries

    There were just five initial public offering (IPOs) in the year, raising £432m, with another £658m coming from follow-on public financings, including a £273m round from GW Pharma. ... 2018’s UK IPOs came fromSensyne Health, Acacia Pharma and

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Oxford PharmaGenesis

Oxford PharmaGenesis is an independently owned HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups....

Latest intelligence

Box 1
Strategic commitment
...
KOL Ambassador Program & Podcast Creation: A Customer Story
...
Animation: Living With
The journey from the patient's perspective...